Despite facing significant pressure from rising medical expenses, Elevance Health —the nation’s second-largest health insurer—reported a first-quarter net income of nearly $1.8 billion. While the company’s earnings surpassed Wall Street expectations, the results highlight a broader, industry-wide struggle: the rising cost of providing healthcare to an increasingly active patient base.
Financial Performance at a Glance
Elevance Health’s quarterly results show a complex tug-of-war between growing revenues and surging expenses.
- Net Income: $1.76 billion (down nearly 17% from $2.18 billion in the same period last year).
- Total Revenue: $50.18 billion (up 2.6% year-over-year).
- Earnings Per Share (EPS): $8, outperforming analyst forecasts.
- Membership: 45.4 million members, a modest increase of less than 1%.
The “Benefit Expense Ratio” Challenge
The most critical metric for health insurers is the benefit expense ratio —the percentage of premium revenue used to pay for medical claims. For Elevance, this ratio climbed to 86.8%.
In a healthy financial environment, insurers typically aim for a ratio in the mid-to-low 80s. The current spike is largely driven by the Medicaid business, though some improvements in Medicare helped mitigate the impact.
Why are medical costs rising?
This trend is not unique to Elevance; it is a systemic issue affecting the entire insurance sector. The primary driver is a phenomenon often described as “pent-up demand.” Following the COVID-19 pandemic, many Americans—particularly older adults—delayed elective surgeries and routine medical treatments. As these individuals return to healthcare providers to address long-neglected issues, the volume and cost of claims have surged, placing immense pressure on insurer margins.
Strategic Shifts and Growth Engines
While medical costs remain high, Elevance is navigating these headwinds through strategic repositioning and diversification.
1. Disciplined Membership Management
The company reported a slight decline in certain segments, such as Medicare Advantage and employer group risk membership. However, leadership characterized this as “disciplined action” intended to prioritize sustainable performance over sheer volume. By focusing on higher-quality, more profitable membership, the company aims to stabilize its long-term margins.
2. The Rise of Carelon
A significant bright spot in the report is the growth of Carelon, Elevance’s healthcare services division.
– Operating Revenue: Rose nearly 8% to $18 billion.
– Key Driver: The scaling of CarelonRx (pharmacy benefit management) and other risk-based service solutions.
This diversification into healthcare services allows Elevance to capture more value across the entire patient journey, reducing its total reliance on traditional insurance premiums.
Looking Ahead: Increased Confidence
Despite the dip in net income compared to the previous year, CEO Gail K. Boudreaux expressed optimism regarding the company’s trajectory. Based on “underlying business strength” and improved visibility into the rest of the year, Elevance raised its full-year adjusted earnings guidance to at least $26.75 per share.
“Our actions are driving more consistent performance and position Elevance Health for continued improvement over time,” stated CEO Gail K. Boudreaux.
Conclusion
Elevance Health is successfully navigating a high-cost medical environment by leveraging its service-based businesses and refining its membership base. While rising healthcare utilization remains a persistent headwind, the company’s ability to exceed profit expectations suggests a resilient business model capable of absorbing increased medical claims.
